In particular, ALDH1A1 enables cancer progression by facilitating drug resistance and fostering resilience of tumor-initiating cells; this applies to cancers driven by RAS/NFκB, FLT3ITD, and mutant P53. Here, ALDH1A1 is linked to neoplasm.